SCHEMBL2493663

SCHEMBL2493663

[NH]C(=O)Oc1ccc2ccccc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.61
▸ MEN1 O00255 4/20 0.61
▸ MAPT P10636 1/20 0.61
▸ TDP1 Q9NUW8 1/20 0.61
▸ ALDH1A1 P00352 2/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54
▸ PTPN7 P35236 1/20 0.52
▸ MMP1 P03956 2/20 0.50
▸ MMP12 P39900 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ FABP7 O15540 1/20 0.49
▸ FABP3 P05413 1/20 0.49
▸ BCHE P06276 1/20 0.49
▸ FAAH O00519 1/20 0.49
▸ EPHX1 P07099 1/20 0.49
▸ MMP2 P08253 1/20 0.49
▸ CYP1A2 P05177 2/20 0.48
▸ CYP2A6 P11509 1/20 0.48
▸ NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21881869 0.83 KMT2A (0.66) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL1809377 0.83 KMT2A (0.66) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL1808182 0.82 KMT2A (0.65) KMT2AMEN1MAPTTDP1ALDH1A1
Naphthalene SCHEMBL1131780 0.81 KMT2A (0.69) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL29937281 0.81 KMT2A (0.69) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL6443500 0.81 KMT2A (0.63) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL1563903 0.81 KMT2A (0.69) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL4877729 0.79 KMT2A (0.61) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL4396167 0.79 KMT2A (0.61) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL12974128 0.79 KMT2A (0.61) KMT2AMEN1MAPTTDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107660202-B Water-soluble prodrugs 大日本住友制药肿瘤公司 2021-12-24 — — CN disclosed
CN-111295368-A Chemically activated water soluble prodrugs 大日本住友制药株式会社 2020-06-16 — — CN disclosed
US-9758480-B2 1-(cycloalkyl-carbonyl)proline derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-09-12 — — US disclosed
US-20150210640-A1 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2015-07-30 — — US disclosed
EP-2876105-A1 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2015-05-27 — — EP disclosed
US-8030499-B2 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-10-04 — — US disclosed
US-20080318923-A1 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-12-25 — — US disclosed
US-RE39420-E1 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 2006-12-05 — — US disclosed
US-6972294-B1 Compounds, their preparation and use NOVO NORDISK, A/S (DK) 2005-12-06 — — US disclosed
US-20040229899-A1 Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) JEPPESEN LONE (DK) 2004-11-18 — — US disclosed
WO-2000063209-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-10-26 — — WO disclosed
WO-2000063153-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-10-26 — — WO disclosed
WO-2000023417-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 — — WO disclosed
WO-2000023451-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 — — WO disclosed
WO-2000023415-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 — — WO disclosed
WO-2000023445-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 — — WO disclosed
WO-2000023416-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 — — WO disclosed
WO-2000023425-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 — — WO disclosed
US-5908858-A OSTEOPOROSIS; LEUKOTRIENE INHIBITOR SANKYO COMPANY, LIMITED (JP) 1999-06-01 — — US disclosed
EP-0799823-A1 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY LIMITED (JP) 1997-10-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210640-A1 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE RB1, F2, SFPQ KMT2A 484/4885MEN1 3514/4885MAPT 4798/4885
US-20080318923-A1 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle AVPR1B, AVPR1A, AVPR2 KMT2A 1662/4885MEN1 527/4885MAPT 672/4885
US-20040229899-A1 Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) PPARG, PPARA, PPARD KMT2A 2849/4885MEN1 4518/4885MAPT 4634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback